A Study to Evaluate the Efficacy and Safety of Erenumab (AMG 334) in Chronic Migraine Prevention
Status:
Completed
Trial end date:
2016-04-28
Target enrollment:
Participant gender:
Summary
To evaluate the effect of erenumab compared to placebo on the change from baseline in the
number of monthly migraine days in adults with chronic migraine.